Introduction {#Sec1}
============

The development of innovative approaches that integrate genomic, proteomic, and metabolomic data has expanded the number of high-priority candidate genes and biomarkers identified for complex diseases, including asthma \[[@CR1]--[@CR5]\]. These strategies, which combine RNA and/or protein and metabolite expression profiling with genetic association studies, are a breakthrough in the search for the biological mechanisms that underlie complex diseases. SNPs that are tightly linked to or capable of directly influencing gene expression represent QTLs that regulate expression of mRNAs (i.e., eQTLs), or production of metabolites and small molecules (i.e., pQTLs) \[[@CR6]--[@CR8]\], respectively. Through QTL mapping, variation in molecular, transcriptomic, and phenotypic traits can be correlated with variation in DNA sequences \[[@CR7], [@CR9]--[@CR11]\]. Correlation of molecular and phenotypic traits can also be informative for inferring molecular networks that contribute to asthma pathogenesis or drug treatment responses.

In this study, we applied integrative methods to investigate the relationship between patient genotype and treatment response to zileuton, a leukotriene modifying agent \[[@CR12]--[@CR14]\]. Leukotrienes are synthesized from arachidonic acid (AA) by 5-lipoxygenase (5-LO) \[[@CR15], [@CR16]\]. After export from the cell, leukotrienes modulate important immunological activities including neutrophil activation, chemotaxis, eosinophil migration and smooth muscle contraction \[[@CR16], [@CR17]\]. Zileuton exerts its effects through inhibition of 5-LO-mediated production of leukotrienes, in particular leukotriene B4 (LTB~4~) \[[@CR18]\]. Clinical response to leukotriene modifiers, including zileuton, is highly variable and repeatable within individuals, suggesting that polymorphic variation in genes in the leukotriene pathway may play a role in zileuton response \[[@CR19]--[@CR21]\]. In particular, SNPs that are significantly associated with both treatment-related clinical outcomes, as well as changes in leukotriene levels may represent important genetic biomarkers.

We hypothesized that genetic variation at the level of unique biological pathways is associated with variability in lung function in response to zileuton. In order to identify sets of genes and pathways that were associated with zileuton response, we first performed a pathway-based analysis using GWAS data obtained from a recent genome-wide investigation of zileuton response \[[@CR22]\]. The advantage of using data identified through GWAS to interrogate biological pathways is that this method enriches for potentially functionally important candidate genes and SNPs that may not have been individually strongly associated with clinical response phenotypes. Having identified a set of candidate genes and pathways related to clinical response to zileuton, we then sought to identify specific QTLs associated with changes in LTB~4~ concentrations post-treatment, as well as changes in global mRNA expression. We next integrated pathway enrichment and QTL information to identify potentially causal candidate genes. Finally, we experimentally validated the expression of selected candidate pathway genes, and determined the activation status of a key pathway of interest.

Materials and methods {#Sec2}
=====================

Genomic datasets {#Sec3}
----------------

### Clinical cohort {#Sec4}

Summary statistics, genome-wide genotype and phenotypic information from a recent GWAS \[[@CR22]\] investigating two placebo-controlled clinical trials of zileuton response (309 subjects) were available for interrogation. For this study, 226,890 SNPs with concordant effect size estimates (β coefficient sign) in both the discovery and replication GWAS \[[@CR22]\] were pursued for pathway analysis.

### Cell lines {#Sec5}

Lymphoblastoid cell lines (LCLs) were available from 800 probands from the Childhood Asthma Management Program (CAMP), a 4 year National Heart Lung and Blood Institute-sponsored clinical trial comparing the efficacy of budesonide vs. nedocromil vs. placebo in 1041 patients \[[@CR23], [@CR24]\]. Genotypes, microarray expression data, and LTB~4~ concentrations from 345 LCLs derived from these patients were used to generate the QTL datasets.

Approach to hypothesis testing {#Sec6}
------------------------------

Statistical approaches for hypothesis testing for each of the core analyses performed in this study are described in Supplemental Table [1](#MOESM1){ref-type="media"}.

Pathway analysis methods {#Sec7}
------------------------

### Gene-based pathway analysis {#Sec8}

For gene-based pathway analysis, genes were analyzed for their enrichment in pathways from KEGG, Pathway Commons and WikiPathways. Query genes were analyzed relative to all genes annotated in the human genome using the hypergeometric test for evaluation of enrichment, and correcting the resulting *P*-values for multiple testing by the Benjamini and Hochberg method \[[@CR25]\]. The resulting pathways were then ranked according to the lowest *P*-value (or FDR *q*-value).

### SNP-based pathway analysis {#Sec9}

For SNP-based pathway analysis, "Improved Gene Set Enrichment Analysis for Genome-Wide Association Studies" (iGSEA-4-GWAS) \[[@CR26]\] (<http://gsea4gwas.psych.ac.cn/>), was used to generate pathways from SNP and *P*-value data. The iGSEA-4-GWAS approach applies an improved gene set enrichment analysis (*i-*GSEA) to GWAS data (SNP *P*-value, odds ratio or other statistics) using SNP label permutation instead of phenotype to enrich for gene sets with high proportion of significant genes \[[@CR26]\]. SNP rsIDs and corresponding --log~10~ *P*-values were mapped to +/− 500 KB from genes annotated to canonical pathways in the Molecular Signatures Database (MSigDB). A nominal iGSEA P value cutoff of 0.01 was specified, and FDR was used to correct for multiple testing \[[@CR26]\]. Pathways meeting a significance threshold of FDR \< 0.25 (to denote the confidence of 'possible' or 'hypothesis') were prioritized.

Cell studies and functional validation methods {#Sec10}
----------------------------------------------

### Cell culture and incubation experiments {#Sec11}

Cellular analyses were performed using lymphoblastoid cell lines (LCLs) that were derived from CAMP. For this study, 100 paired LCLs were cultured in growth medium (RPMI 1640, 5% FBS, 1% L-Glutamine, and 1% antibiotic--antimycotic) in a T25 flask in a 37 °C, 5% CO~2~ incubator. The cells were grown to a density of \~200,000 viable cells/mL. For stimulation experiments, 10--13 million cells were resuspended in 32 ml (\~350 K/ml) regular growth medium and 2.5 ml were dispensed into each well of two 6-well culture plates (\~850 K/well). Three wells of each 6- well plate were treated with 10 mM arachidonic acid or 2.5 uL of 100% ethanol. After incubating for 12 hours, the supernatant was removed and cells were treated with 1 µM zileuton (ZIL) or 2.5 uL of 100% ethanol for 6 hours. After treatment, the cells were harvested and spun down for stimulation. Cell stimulations were performed by resuspending cell pellets in phosphate buffered saline (PBS ( + Ca^++^, + Mg^++^)) containing 0.1 mM calcium ionophore and 4 mM arachidonic acid and incubated at 37̊ °C for 5 minutes. Cells were placed on ice and supernatants were harvested for quantification of LTB~4~ concentration using the LTB~4~ Express EIA kit (Caymen Chemical), while the cell pellets were lysed for RNA extraction using the RNeasy Mini Kit (Qiagen).

### LTB~4~ enzyme-linked immunosorbent assay (ELISA) {#Sec12}

An LTB~4~-specific ELISA was performed using a commercial Leukotriene B4 Enzyme Immunoassay Kit, according to the manufacturer's instructions. LTB~4~ concentrations in each sample were determined using fluorimetry at 405 nm wavelength, and normalized to a standard curve.

### Microarray analysis {#Sec13}

For microarray, 200 ng RNA specimens were amplified using Illumina's TotalPrep RNA Amplification kit (Ambion) according to the manufacturer's protocol, and 750 ng of each amplified specimen were hybridized onto a Sentrix BeadChip Array for Gene Expression HumanRef12_V4, according to the manufacturer's protocol. The BeadChip Array was scanned using Illumina's BeadArray Reader. Quality control analysis of array data was performed using Illumina's GenomeStudio v2009.1 Software, Gene Expression Module version 1.1.1 and iCheck_0.1.4.

Western analysis {#Sec14}
----------------

For Western blot experiments, cell cultures were harvested after 24 hours of treatment (as described above) and lysed using RIPA buffer with protease and phosphatase inhibitors added. Cell lysates were prepped under reducing conditions per the Life Technologie's iBind™ Western System protocol. Western blots were either probed with a mouse anti-PI3K primary antibody (Abcam), a rabbit anti-AKT primary antibody (Cell Signaling Technology) or a rabbit anti-phospho-AKT primary antibody (Cell Signalling Technology). AKT and phospho-AKT blots were probed with an HRP conjugated goat anti-rabbit IgG secondary antibody (Abcam), while PI3K blots were probed with an HRP conjugated goat anti-mouse IgG secondary antibody (Life Technologies). β-actin was used as a protein loading control and was probed using a mouse anti- β-actin primary antibody (Life Technologies) and an HRP conjugated goat anti-mouse IgG secondary antibody (Life Technologies). Results were visualized using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) and captured using a G:Box (Syngene). Quantitative analysis was performed using GeneTools image analysis software (Syngene).

Quantitative trait loci (QTL) analyses {#Sec15}
--------------------------------------

### LTB~4~ QTL (pQTL) Analysis {#Sec16}

LTB~4~ concentrations from 100 LCLs were obtained as described above. A linear regression model was used to associate individual SNP genotypes (\>500,000 SNPs) from each sample with LTB~4~ concentration values, in corresponding zileuton-treated and ethanol-treated samples. PLINK v.1.0.7 was used to exclude SNPs with \>10% missing data, a minor allele frequency \<5%, and a paired *r* ^2^ \> 0.9, resulting in 463,791 SNPs remaining for analysis. The effect of each locus on LTB~4~ levels was analyzed using PLINK v.1.0.7, assuming an additive genetic model, and adjusting for sex and race. Significance of association with LTB~4~ concentration values was assessed for each SNP using the Chi-square test, and a Bonferroni corrected significance threshold was set at 1.1 × 10^−07^ for 463,791 tests. SNPs with nominally significant associations (*P *\< 0.05) in the ethanol-treated group were excluded from further analysis. For comparative analysis in samples from a relevant clinical population taking zileuton, a subset of 22,505 pQTLs that were unique to the zileuton treatment group, and that were at least nominally significant based on association *P*-values \< 0.05, were also investigated for overlap using data from a recent GWAS of zileuton response \[[@CR22]\]. SNPs that were at least nominally significant for both pQTL and GWAS analyses (pQTL and GWAS *P* values \< 0.05) were selected for pathway analyses.

### Expression QTL (eQTL) analysis {#Sec17}

To evaluate the effect of zileuton treatment on gene expression, we evaluated 345 paired LCLs treated with zileuton or ethanol. After stimulation with arachidonic acid, each pair was treated with zileuton or ethanol (sham), as described above. The expression levels of 47,131 gene probes were measured using Illumina's HumanHT-12_V4 chip, and 36,993 gene probes were retained after quality control procedures. The probe expression levels were log~2~-transformed and quantile normalized, and the log~2~ difference in expression level between zileuton treated and sham treated cell lines was obtained for each sample. Paired *t*-test was used to evaluate differential gene expression in samples treated with zileuton vs. sham, and the false discovery rate (FDR) was applied to correct for multiple testing. Of 36,993 probes, 5123 probe sets achieved nominal significance (*P* \< 0.05) based on paired *t*-test, of which 918 probes surpassed the FDR threshold of 0.05. We next extracted genotypes (505,066 SNPs) from 345 samples, using the genome-wide genotype data from the subjects from whom the individual LCLs were derived (CAMP dataset). SNPs that failed tests for Hardy-Weinberg, missingness, or with minor allele frequency \< 0.05 were excluded from the final data set, resulting in 459,261 remaining SNPs. No population substructure was detected by EIGENSTRAT. To identify eQTLs, we used the *MatrixEQTL* R package to test the association of SNP genotype with the log~2~ difference in expression for a gene probe, adjusting for age, gender, and the top four principal components of the expression data. The human genome version 19 annotation for both genes and SNPs was used. For each gene probe, all SNPS within a 50 KB range from flanking genic regions wherein a given probe resided were used to test for *cis*-effects. All SNPs outside this range, and on other chromosomes, were used to test for *trans*-effects. To increase the scope of potential inputs that could better inform pathway analyses, with *a priori* knowledge that we could generate functional models to validate the subsequent results, we chose a raw *P* value cut-off of 1 × 10^−08^, and applied a FDR \< 0.05 as the multiple test correction threshold.

Results {#Sec18}
=======

Pathway analysis of zileuton response GWAS {#Sec19}
------------------------------------------

An overview of the study design is shown in Fig. [1](#Fig1){ref-type="fig"}. To identify molecular pathways related to zileuton clinical response, we first evaluated existing data from a recent GWAS of zileuton response in 309 asthmatics (Abbott-Zileuton GWAS) \[[@CR22]\]. Zileuton response was defined as a change in lung function, as measured by forced expiratory volume in one second from baseline to 8 weeks of zileuton therapy (∆FEV~1~) \[[@CR22]\]. Data from 226,890 SNPs having the same direction of effect (β) in the discovery and replication GWAS were evaluated using a SNP-based pathway analysis and gene set enrichment analysis. A total of 212,364 SNPs were annotated to 15,117 genes and mapped to 523 gene sets, resulting in four enriched pathways (FDR \< 0.25): "PLC PATHWAY", "CASPASE PATHWAY" and "SIG IL4 RECEPTOR IN B LYMPHOCYTES" and "INNATE IMMUNE RESPONSE" (Table [1](#Tab1){ref-type="table"})).Fig. 1Overview of study design Table 1Pathways enriched in GWAS of zileuton responsePathway rankPathway namePathway descriptionPathway sourceGene symbolSNP IDAssociation log*P* value1PLC pathwayPhospholipase C hydrolyzes the membrane lipid PIP~2~ to DAG to activates protein kinase C, and IP~3~, causing calcium influxBioCarta*PIK3R1*rs13443674.03*PLCB1*rs23271203.09*VAV1*rs3470332.88*PRKCA*rs2288852.47*PIK3CA*rs16072372.342CASPASE pathwayCaspases are cysteine proteases active in apoptosisBioCarta*LMNB1*rs37631565.47*CYCS*rs102399074.05*APAF1*rs125811194.01*LMNB2*rs48068493.60*GZMB*rs81929173.31*LMNA*rs99192562.433SIG IL4 Receptor in B LYMPHOCYTESGenes related to IL~4~ receptor signaling in B lymphocytesUCSD Signaling Gateway*PIK3R1*rs13443674.03*JAK3*rs72504233.59*IRS1*rs75745383.38*IL4R*rs99443403.36*BCL2*rs80963803.13*PDK1*rs92879572.96*SOCS1*rs4086652.51*PIK3CA*rs16072372.34*IRS2*rs95215222.33*AKT3*rs30069282.32*JAK1*rs127435992.15*GSK3B*rs37323612.054Innate immune responseInnate immune responsesAMIGO*CD1D*rs8590051.35*SFTPD*rs22436391.82Association log*P* value corresponds to the adjusted, log-transformed GWAS *P* value for the SNP used in the pathway database query

QTL mapping {#Sec20}
-----------

### QTL identification and annotation {#Sec21}

In an effort to characterize variability in the leukotriene production pathways that could potentially underlie differential responsiveness to zileuton, we evaluated global gene expression and/or LTB~4~ production in LCLs treated with zileuton or ethanol (control) in paired LCLs derived from asthmatic patients, and mapped QTLs for both treatment groups. LCLs were first stimulated with arachidonic acid (AA) to stimulate LTB~4~ production, and were then treated with either zileuton or ethanol. For pQTL analyses, LTB~4~ concentrations in 100 paired LCLs were determined by ELISA. As expected, following activation with AA, LCLs treated with zileuton showed a significant but variable decrease in LTB~4~ production (\[LTB~4~\]~mean_etoh~ = 270 ± 271 ng/mL vs. \[LTB~4~\]~mean_zileuton~ = 74.5 ± 66.9 ng/mL; *P* \< 0.0001) (Supplemental Fig. [1A](#MOESM3){ref-type="media"}). We next integrated genome-wide genotypes (463,791 QC-validated SNPs) from each of the LCL samples with LTB~4~ concentrations from both treatment groups to identify zileuton-related pQTLs. A set of 22,505 SNPs specific to the zileuton-treated group were nominally associated (unadjusted P \< 0.05) with differential LTB~4~ production, of which eight SNPs remained significant following correction for multiple testing; the top 100 pQTLs, ranked by their P-values, are listed in Supplemental Table [2](#MOESM1){ref-type="media"}. Of the significant pQTLs, all were associated with persistent LTB~4~ production despite treatment with zileuton (i.e., poorer responsiveness) (Supplemental Table [2](#MOESM1){ref-type="media"}). Two of the top pQTLs (rs10743992 and rs6485597) were annotated to introns within *cAMP responsive element binding protein-like 2* (*CREBL2*) and *PR domain-containing protein 11* (*PRDM11*) genes, while a third SNP (rs2823730) was found within a long intergenic non-protein coding RNA, *LINC00478* (Supplemental Table [2](#MOESM1){ref-type="media"}).

For eQTL mapping, 345 paired LCLs were treated with AA, followed by treatment with zileuton or ethanol as described above and in Methods, and gene expression levels for both treatment groups were measured using microarray. We identified 262 trans-eQTLs that met an unadjusted significance threshold of *P* \< 1 × 10^−08^. The top four eQTLs also met FDR \< 0.05. The 262 eQTLs regulated the expression of 161 unique genes, of which 132/262 eQTLs (50.3%) were annotated to 81 genes. The top 50 eQTLs are listed in Supplemental Table [4](#MOESM1){ref-type="media"}, and the four eQTLs meeting FDR \< 0.05 are shown in Figs. [2b--e](#Fig2){ref-type="fig"}. Four of the genes in which the 262 eQTLs resided were also significantly differentially expressed in LCLs following zileuton treatment (FDR \< 0.05). A quantile-quantile (QQ) plot (Fig. [2a](#Fig2){ref-type="fig"}) of the log-difference in gene expression related to zileuton vs. ethanol treatment revealed a significant deviation from the expected for the trans-eQTL analysis (Figs. [2b--e](#Fig2){ref-type="fig"},*boxplots*). Both rs12762462 and rs12251868 were annotated to *G protein-coupled receptor 158* (*GPR158)*, and are predicted to regulate the expression of *selectin L* (*SELL)* (Supplemental Table [4](#MOESM1){ref-type="media"}). rs10495426 is an intergenic SNP that is predicted to regulate *metal response element binding factor 2* (*MTF2)* (Supplemental Table [4](#MOESM1){ref-type="media"}). rs12414020 was annotated to *neuregulin 3* (*NRG3)* and is predicted to regulate the expression of *galanin and galanin message-associated peptide (GMAP) prepropeptide* (*GAL)*. In LCLs, all of these eQTLs significantly reduced the expression of the genes they are predicted to regulate following treatment with zileuton (Figs. [2b--e](#Fig2){ref-type="fig"}). However, these signals appeared to be driven by a small number of subjects who carried homozygous variant genotypes. We identified 10 individuals who carried the homozygous variant genotypes for the four eQTLs (three for rs10495426, three for rs12762462 and rs12251868 (the same individuals for both), and four for rs12414020) whose removal resulted in *P*-values that remained nominally significant, but were no longer significant after controlling for multiple testing (FDR \< 0.05) (data not shown).Fig. 2eQTLs for Zileuton Response. **a** The Q--Q plot shows the relationship between observed vs. expected (diagonal; gray line) *P*-values for 735,488 local (red line/dots) and 13,009,811,306 distant (blue line/dots) gene-SNP *P* values. Jittered boxplots **b-e** show individual data points (red dots) and medians (±IQR) of log~2~ mRNA expression values (zileuton:ethanol) (*y*-axis), stratified by genotype category ("0" = reference allele; "1" = heterozygous variant; "2" = homozygous variant) (*x*-axis): **b** Expression of probe 6940358 (gene symbol = *SELL*) by rs12762462 genotype; **c** Expression of probe 2760255 (gene symbol = *MTF2*) by rs10495426 genotype; **d** Expression of probe 6940358 (gene symbol = *SELL*) by rs12251868 genotype; **e** Expression of probe 60452 (gene symbol = *GAL*) by rs12414020 genotype

### QTL integration and pathway analysis {#Sec22}

There were 22,505 nominally significant pQTLs that were unique to the zileuton treatment group; these were evaluated to determine whether any were also associated with zileuton-related changes in lung function, using data from a GWAS of zileuton response in 309 asthmatics \[[@CR22]\]. A total of 1060 SNPs were nominally associated with differential LTB~4~ production, as well as zileuton-related 8-week ∆FEV~1~ based on pQTL and GWAS *P* values \< 0.05. The top 50 pQTLs are shown in Supplemental Table [3](#MOESM1){ref-type="media"}. Pathway analysis of the 1060 pQTLs identified two major 'hubs' inclusive of the top 10 significantly enriched pathways: phosphatidyl inositol signaling (via *phosphatidylinositide 3-kinase*  (*PI3K)*) and catenin signaling. The phosphatidyl inositol signaling (via *PI3K*) hub included pathways for "FCγR-mediated phagocytosis", "FcεR1 signaling pathway", "Focal adhesion", "Neurotrophin signaling pathway", "Regulation of actin cytoskeleton", "Pathways in cancer" and "Type II diabetes mellitus", while the catenin signaling hub included pathways for "Adherens junction", "Endometrial cancer", "Pathways in cancer", "Arrhythmogenic right ventricular cardiomyopathy (ARVC)" (shown in Table [2](#Tab2){ref-type="table"}). These pathways comprise 31 unique genes, of which *PI3K* isoforms (*PIK3R1* and *PIK3R5*) were most highly enriched relative to all other genes (Supplemental Fig. [2](#MOESM4){ref-type="media"}).Table 2Pathways enrichment analysis of pQTLs for LTB~4~ production in asthmatic LCLsPathway rankPathway nameGene symbolSNP IDAdjusted pathway *P* value1Fc gamma R-mediated phagocytosis*PRKCE*rs21763471.41E-05*PRKCE*rs1878384*VAV1*rs347033*VAV3*rs6680436*WASF3*rs9512311*PIK3R5*rs516434*PIK3R1*rs3730082*PIK3R1*rs16897561*PRKCD*rs17052826*DOCK2*rs2161148*SYK*rs12550873*SYK*rs290212*SYK*rs4744505*SYK*rs13336302Fc epsilon RI signaling pathway*PRKCE*rs21763472.26E-05*PRKCE*rs1878384*VAV1*rs347033*VAV3*rs6680436*PIK3R5*rs516434*PIK3R1*rs3730082*PIK3R1*rs16897561*PRKCD*rs17052826*MAPK14*rs2237093*SYK*rs12550873*SYK*rs290212*SYK*rs4744505*SYK*rs13336303Focal adhesion*VAV1*rs3470335.52E-05*VAV3*rs6680436*PIK3R5*rs516434*ITGA6*rs7584977*ITGA6*rs7596259*PIK3R1*rs3730082*PIK3R1*rs16897561*RELN*rs362732*COL4A1*rs631428*ACTN1*rs2300875*ITGAV*rs3738919*EGFR*rs13244925*SHC2*rs7408714Adherens junction*WASF3*rs95123118.58E-05*ACTN1*rs2300875*PTPRB*rs2717418*PTPRM*rs2005039*EGFR*rs13244925*TCF7L2*rs3814573*CTNNA2*rs383452*CTNNA2*rs18169095Endometrial cancer*PIK3R5*rs5164340.0001*EGFR*rs13244925*TCF7L2*rs3814573*PIK3R1*rs3730082*PIK3R1*rs16897561*CTNNA2*rs383452*CTNNA2*rs1816909*AXIN2*rs45411116Neurotrophin signaling pathway*MAP2K5*rs37847160.0003*PIK3R5*rs516434*PIK3R1*rs3730082*PIK3R1*rs16897561*PRKCD*rs17052826*NTRK3*rs2279409*NTRK3*rs3784410*MAPK14*rs2237093*NTRK2*rs4486281*SHC2*rs7408717Regulation of actin cytoskeleton*VAV1*rs3470330.0003*VAV3*rs6680436*PIK3R5*rs516434*ITGA6*rs7584977*ITGA6*rs7596259*FGF18*rs4620037*PIK3R1*rs3730082*PIK3R1*rs16897561*ACTN1*rs2300875*ITGAV*rs3738919*F2R*rs153311*EGFR*rs132449258Pathways in cancer*GLI3*rs22991420.0004*GLI3*rs846266*GLI3*rs846335*PIK3R5*rs516434*ITGA6*rs7584977*ITGA6*rs7596259*FGF18*rs4620037*PIK3R1*rs3730082*PIK3R1*rs16897561*AXIN2*rs4541111*COL4A1*rs631428*ITGAV*rs3738919*ETS1*rs7115613*ETS1*rs4628683*EGFR*rs13244925*TCF7L2*rs3814573*CTNNA2*rs383452*CTNNA2*rs18169099Arrhythmogenic right ventricular cardiomyopathy (ARVC)*ACTN1*rs23008750.0005*ITGAV*rs3738919*CACNB2*rs1571787*ITGA6*rs7584977*ITGA6*rs7596259*TCF7L2*rs3814573*CTNNA2*rs383452*CTNNA2*rs181690910Type II Diabetes mellitus*PRKCE*rs21763470.0006*PRKCE*rs1878384*PIK3R5*rs516434*CACNA1E*rs1999838*PIK3R1*rs3730082*PIK3R1*rs16897561*PRKCD*rs17052826

We next evaluated whether any of the 262 eQTLs were also present (overlapping) within the set of 22,505 pQTLs related to LTB~4~ production. We identified 22 overlapping eQTL/pQTL relationships, including three of the top-ranked eQTLs (rs12762462, rs10495426 and rs12251868 (Supplemental Table [4](#MOESM1){ref-type="media"})); 18/22 eQTLs/pQTLs were annotated to 7 genes (Supplemental Table [5](#MOESM1){ref-type="media"}). However, none of the 262 eQTLs were also included among the set of 1060 pQTLs that were jointly associated with LTB~4~ production and zileuton clinical response; as such, they could represent unique determinants of zileuton pharmacological response vs. clinical response.

Pathway analysis of the 262 eQTLs identified seven significantly enriched pathways (Table [3](#Tab3){ref-type="table"}). Notably, these pathways also coincided with those for the pQTLs (Table [3](#Tab3){ref-type="table"}, Supplemental Table [4](#MOESM1){ref-type="media"}). Among the pathways, several genes that directly or indirectly interacted with the PIK3 signaling pathway hub were also present, e.g., *calcium voltage-gated channel auxiliary subunit beta 4* (*CACNB4)* and *fibroblast growth factor* (*FGF)* isoforms within the "MAPK Signaling Pathway", and *F* *GF* isoforms and *integrin subunit beta 6* (*ITGB6)* within the "Regulation of the actin cytoskeleton" pathway, which act upstream of the phosphatidylinositol signaling pathway (Table [3](#Tab3){ref-type="table"}).Table 3Pathway enrichment analysis of zileuton-related eQTLsPathway rankPathway nameGene symbolSNP IDAdjusted pathway *P* value1Arrhythmogenic right ventricular cardiomyopathy (ARVC)*ITGB6*rs134038260.0036*CDH2*rs8087457*CDH2*rs643555*CACNB4*rs168305002Purine metabolism*GDA*rs107810760.0162*FHIT*rs6781028*PDE4B*rs120321173Endocytosis*SH3GL3*rs26379780.017*FLT1*rs10507385*RAB31*rs22841374Regulation of actin cytoskeleton*MYH9*rs96104890.017*FGF14*rs8000905*FGF14*rs1336724*FGF14*rs7989386*FGF14*rs1928510*ITGB6*rs134038265MAPK signaling pathway*FGF14*rs80009050.018*FGF14*rs1336724*FGF14*rs7989386*FGF14*rs1928510*CACNB4*rs16830500*PLA2G6*rs738322*PLA2G6*rs1329856Hypertrophic cardiomyopathy (HCM)*ITGB6*rs134038260.018*CACNB4*rs168305007Dilated cardiomyopathy*ITGB6*rs134038260.018*CACNB4*rs168305008Focal adhesion*ITGB6*rs134038260.05*FLT1*rs10507385

To determine the functional importance of these pathways in LCLs, the expression of 68 genes that were collectively identified through pathway analyses (listed in Tables [1](#Tab1){ref-type="table"}--[3](#Tab3){ref-type="table"} **)** was validated by microarray analysis of zileuton treated vs. ethanol treated LCLs. Of these, 8 genes were differentially expressed (zileuton vs. ethanol) at a nominal significance threshold, with one gene, *suppressor of cytokine signaling 1* (*SOCS1)*, remaining significant following multiple test correction (Supplemental Table [7](#MOESM1){ref-type="media"}).

Experimental validation of candidate pathway and genes {#Sec23}
------------------------------------------------------

### Pathway prioritization {#Sec24}

A pathway analysis of 1060 joint pQTLs had identified phosphatidyl inositol signaling via *PI3K* as a major hub, where *PI3K* isoforms were more frequently enriched among pathway genes (Table [2](#Tab2){ref-type="table"}; Supplemental Fig. 2). In addition, by integrating pQTL and eQTL data, we also identified several genes that interact with *PIK3* (Table [3](#Tab3){ref-type="table"} and Supplemental Table [4](#MOESM1){ref-type="media"}), namely *phosphodiesterase 4B* (*PDE4B), fragile histidine triad (FHIT), myosin heavy chain 9 (MYH9), cadherin 2 (CDH2)*, and others. Furthermore, we show that among the 8 differentially expressed pathway genes, *PIK3CA* expression was reduced, albeit at a nominal significance level (Supplemental Table [7](#MOESM1){ref-type="media"}). As the collective analyses pointed toward a rationale for prioritizing the PI3K signaling pathway (which was further emphasized due to its relevance as a potential therapeutic target for asthma \[[@CR27], [@CR28]\]), we hypothesized that differential zileuton responsiveness could be related to changes in the expression and activation of genes within this pathway. We therefore next validated the PI3K pathway using a cellular model of zileuton response.

### Pathway validation {#Sec25}

To validate the PI3K pathway in a clinically relevant cellular model, we first selected LCLs that had demonstrated different magnitudes of treatment responses to zileuton, based on LTB~4~ production. Four LCLs that had demonstrated significant down-regulation of LTB~4~ production following zileuton treatment (mean fold change = 6.8 (termed "good responders")) and four LCLs that demonstrated less than 2-fold change in LTB~4~ concentrations following zileuton treatment (mean fold change = 1.2 (termed "poor responders")) were selected for profiling (Supplemental Fig. [1B](#MOESM3){ref-type="media"}).

A consequence of PI3K pathway activation is an increase in expression of phosphorylated AKT (phospho-AKT), relative to the un-phosphorylated AKT protein \[[@CR29], [@CR30]\]. To evaluate the activation status of this pathway, we compared the expression of AKT, phospho-AKT and PI3K proteins following treatment with fetal bovine serum (FBS), zileuton, or sham (ethanol), in the two groups of LCLs possessing differential LTB~4~ production following zileuton treatment (i.e., 'good' and 'poor' responders). For both LCL groups, treatment with fetal bovine serum (FBS), a pathway activator (Fig. [3](#Fig3){ref-type="fig"}, red bars), increased expression of all three proteins relative to sham (Fig. [3](#Fig3){ref-type="fig"}, green bars), with the greatest increase in AKT and phospho-AKT expression values in the 'poor' responders (Fig. [3](#Fig3){ref-type="fig"}). Compared with sham treatment, zileuton treatment did not significantly increase expression of phospho-AKT in the 'good' responder LCLs (Fig. [3](#Fig3){ref-type="fig"}, blue bars). In contrast, relative to 'good' responders, expression of phospho-AKT was selectively increased by 64% in the 'poor' responder group following zileuton treatment (*P* = 0.037) (Fig. [3](#Fig3){ref-type="fig"}). Otherwise, the expression levels of AKT, phospho-AKT and PI3K did not significantly differ across treatment groups (Fig. [3](#Fig3){ref-type="fig"}). These results suggest that, compared with LCLs that responded well to zileuton inhibition, the PI3K pathway is activated in 'poor' responder LCLs, at basal levels, as well as in response to zileuton treatment.Fig. 3Validation of PIK3CA pathway activation in asthmatic LCLs with differential responses to zileuton. The barplots show normalized mean expression levels ± SEM for AKT (left plot), phospho-AKT (center plot) and PIK3CA (right plot) in 'good' and 'poor' responders (labels, *x*-axis), by treatment category (FBS = red; Sham (ethanol) = green; Zileuton = blue)

### Differential gene expression related to zileuton treatment {#Sec26}

The top 50 differentially expressed probe sets (genes) are listed in Supplemental Table [6](#MOESM1){ref-type="media"}. Among the 918 probe sets, *PIK3CA* (T-statistic = −2.0; *P* = 0.044) and *AKT1* (T-statistic = −3.2; *P* = 0.0015) demonstrated an overall reduction of expression in the zileuton treated LCLs relative to sham, across 345 LCLs. However, expression of these genes from the subset of 'good' and 'poor' responder LCLs was congruent with protein expression values for zileuton vs. ethanol treated LCLS (Supplemental Fig. [3](#MOESM5){ref-type="media"}). Notably, the mRNA and protein expression of AKT (zileuton:ethanol) was reduced in both 'good' and 'poor' responder groups, while the expression of PIK3CA (zileuton:ethanol) was reduced only in the 'good' responders (Supplemental Fig. [3](#MOESM5){ref-type="media"}).

Discussion {#Sec27}
==========

We applied pathway analysis in an integrative approach, combined with experimental validation in a relevant cellular model, to identify candidate genes and pathways underlying clinical and pharmacological (cellular) response to zileuton, a leukotriene inhibitor prescribed for asthma treatment. Using data from a recently published GWAS of zileuton response in asthmatics \[[@CR22]\], we first utilized an improved gene set enrichment analysis (*i-*GSEA) algorithm, which accounts for the combined effects of SNPs/genes with modest effect sizes, and identified four significantly-enriched pathways containing 23 unique genes that collectively represent coordinated pathways related to lipid mediator signaling, leading to cellular growth and survival. Due to the high level of cross talk among these pathways, multiple genes with important regulatory roles in lipid mediator signaling appeared in more than one pathway (e.g., *PIKC3A*), suggesting that they may be biologically relevant for zileuton treatment responses. The most highly ranked pathway (FDR = 0.022, Table I) comprised phosphoinositide 3-kinases (PI3K) lipid signaling molecules. The PI3K family members phosphorylate the inositol rings of phosphoinositide lipids, influencing vesicle trafficking, cell proliferation, and migration \[[@CR31]\]. Akt is also an important co-regulator of PI3K signaling leading to leukotriene production, and the activity of PLA~2~ is necessary for conversion of AA to 5-LO substrates. Together, these results suggest that key regulatory genes within molecular signaling cascades that regulate the production and signaling of lipid mediators are related to zileuton response in patients.

We subsequently replicated these pathways and identified a set of SNPs that are strongly associated with zileuton-related LTB~4~ production in LCLs derived from asthmatic patients (pQTLs). Among the top SNP associations that surpassed FDR, we identified rs10743992 and rs6485597 in  *cAMP responsive element binding protein-like 2 (* *CREBL2)* and *PR/SET domain 11* (*PRDM11)* that were associated with a dramatic increase in LTB~4~ production following zileuton treatment (Table [2](#Tab2){ref-type="table"}). Both rs6485597 and rs10743992 are in complete LD with regulatory and non-synonymous coding SNPs that are also present within these genes, suggesting a potential functional role for *CREBL2* and *PRDM11* (data not shown). Through pathway analysis of pQTL data, we identified numerous genes within the CREB signaling pathway, including *CREB1* (Table [2](#Tab2){ref-type="table"}). These data suggest that CREB-mediated signaling events are involved in zileuton pharmacological response.

Pathway analysis revealed an enrichment of pathways for lipid signaling and cellular migration in response to immune activation. From the 68 genes identified by pathway analysis (shown in Tables [1](#Tab1){ref-type="table"}--[3](#Tab3){ref-type="table"}) eight were significantly differentially expressed in zileuton vs. ethanol treated LCLs (Supplemental Table [7](#MOESM1){ref-type="media"}). Included with these, as well as a majority of the pathways in Tables [1](#Tab1){ref-type="table"}--[3,](#Tab3){ref-type="table"} is *PIK3CA*, a key mediator of phospholipid signaling that is crucial to the production of leukotrienes. *PIK3CA* encodes the 110 kDa catalytic subunit of PI3K and relies on ATP to phosphorylate PtdIns, PtdIns4P and PtdIns \[[@CR4], [@CR5]\]P~2~. These phosphorylated lipids activate downstream targets that in turn activate transcriptional regulators such as CREB, leading to the transcription of genes involved in cell proliferation and survival. We also identified PLC activity as a shared pathway in both pQTL analyses. PLC directly affects LTB~4~ production through conversion of PI to AA, the substrate of 5-LO and precursor of LTB~4~. Together, these data suggest that *PIK3CA* pathway activity may represent a functional network that determines the pharmacological and clinical response to leukotriene modifiers. Furthermore, the production of LTB~4~ in zileuton-treated cells demonstrated high variability (Supplemental Fig. [1](#MOESM3){ref-type="media"}). We subsequently validated the PIK3CA pathway in asthmatic LCLs with differential production of LTB~4~ in response to zileuton. We found that there was significant expression of the activated target of PI3K, phospho-AKT, which was selectively upregulated only in the 'poor' responder group (Fig. [3](#Fig3){ref-type="fig"}). Relative to ethanol, zileuton-treated LCLs also showed increased mRNA and protein expression of PIK3CA, in 'poor' responders only (Supplemental Fig. [3](#MOESM5){ref-type="media"}). Collectively, these data suggest that zileuton responses can be regulated by PI3K pathway activity, and that the pathway is differentially activated in individuals with poorer zileuton responses. From a mechanistic perspective, the 'poor' responders would be expected to have increased activation of PIK3CA and its targets, in parallel with increased LTB~4~ production that is resistant to zileuton inhibition. Higher concentrations of LTB~4~ would be available to bind to cell surface, G-protein coupled receptors, leading to increased PIK3CA signaling and resulting in increased proliferation of pro-inflammatory responses mediated by leukotriene activity. In contrast, our data indicate that 'good' responders would appropriately limit LTB~4~ production following zileuton inhibition, showing correspondingly diminished activity of this pathway due to reduced LTB~4~ concentrations.

This study is the first to report a role for zileuton in modulating the PI3K pathway in adults with asthma, for which zileuton is clinically used. However, a recent study showed that zileuton could selectively up-regulate phosphorylated Akt expression and down-regulate the over-expression of NF-KB p65 and COX-2, in a rat model of ischemic brain damage \[[@CR32]\]. This finding is consistent with our observation that zileuton boosted AKT and phospho-AKT expression in samples from 'poor' responders (Fig. [3](#Fig3){ref-type="fig"}) and provides additional evidence for interaction of zileuton and the PI3K pathway.

While our results pointed toward a role for the PI3K pathway, we also identified four eQTLs that significantly reduced the expression of *SELL*, *MTF2*, and *GAL*, none of which have been annotated to the canonical PI3K pathway. While these signals were driven by a small number of subjects with homozygous variant genotypes, removal of these subjects did not alter the nominal significance of the four eQTLs. There is evidence that these genes may interact with the PI3K pathway, as well as with the CREB signaling pathway. For example, *SELL* is part of a co-expression network that includes *PI3KCA, PIK3CG* and *PIK3R1* \[[@CR33]\], and its protein product physically interacts with PRKCQ, which in turn interacts with PIK3CA through targeting CD28 and RASGRP3 \[[@CR34]\]. MTF2 and CREB1 are also predicted to physically interact \[[@CR35]\]; in addition, MTF2 interacts with PIK3R3 \[[@CR36]\] which directly targets PIK3CA \[[@CR36], [@CR37]\]. Finally, as both GAL and PIK3CA are both activated by binding guanosine triphosphate (GTP), they are co-regulated through the G protein coupled receptor signaling cascade and may also have synergistic molecular roles. For example, GAL receptors can activate the phosphatidylinositol (PtdIns) signaling pathway, and there is evidence that PC12 apoptotic cell death mediated through Gal2R may be dependent on PI3K \[[@CR38]\]. Further work is needed to ascertain the roles of these genes in P13K signaling in the context of leukotriene modifier response in asthma.

In summary, we used a multi-tiered, integrative pathway analysis of GWAS, eQTL, pQTL, and clinical data to prioritize pathways of interest, and functionally validated a candidate pathway with implications in asthma biology. This approach provides a means to identify novel biology for complex diseases and drug response phenotypes.
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